Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Background: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula...

Full description

Bibliographic Details
Main Authors: Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, Rebekah Pennington, Barry Hounsome, Ellen Lever, Andrew Metry, Edith Poku, Yit Yang, Simon P Harding, Andrew Lotery, Usha Chakravarthy, John Brazier
Format: Article
Language:English
Published: NIHR Journals Library 2021-06-01
Series:Health Technology Assessment
Subjects:
macular oedema
central retinal vein occlusion
bevacizumab
ranibizumab
aflibercept
vegf
anti-vegf
cost-effectiveness
retinal non-perfusion
randomised controlled trial
non-inferiority
clinical effectiveness
visual acuity
intravitreal
safety
adverse events
Online Access:https://doi.org/10.3310/hta25380

Internet

https://doi.org/10.3310/hta25380

Similar Items